Daratumumab, Bortezomib, and Dexamethasone for Treatment of Patients with Relapsed or Refractory Multiple Myeloma and Severe Renal Impairment: Results from the Phase 2 GMMG-DANTE Trial
Authors:
- Lisa B. LeypoldtLLLisa B. Leypoldt
- Maria GavriatopoulouMGMaria Gavriatopoulou
- Britta BesemerBBBritta Besemer
- Hans SalwenderHSHans Salwender
- Marc S. RaabMRMarc S. Raab
- Axel NogaiANAxel Nogai
- Cyrus KhandanpourCKCyrus Khandanpour
- Volker RundeVRVolker Runde
- Anna JauchAJAnna Jauch
- Manola ZagoMZManola Zago
- Peter MartusPMPeter Martus
- Hartmut GoldschmidtHGHartmut Goldschmidt
Open Access
Abstract
Renal function impairment (RI) is a common complication in multiple myeloma (MM). However, limited data exist on the safety and efficacy of anti-MM regimens in patients with severe RI, as these patients are frequently excluded from clinical trials. This investigator-initiated multicentric phase II GMMG-DANTE trial evaluated daratumumab, bortezomib, and dexamethasone (DVd) in relapsed or refractory (r/r) MM patients with severe RI. r/rMM patients with ≥1 prior treatment line and a GFR 2 or undergoing hemodialysis were eligible and received eight cycles of DVd followed by daratumumab maintenance. The trial closed prematurely after 22/36 planned patients. The primary endpoint was overall response rate (ORR). Median age of patients was 70 (range 55–89) years, with a median GFR of 20.1 mL/min/1.73 m2 (interquartile range, 9.4–27.3 mL/min/1.73 m2), and eight patients under hemodialysis. Median number of prior lines was two (range 1–10). The trial was successful, albeit with premature termination, as it met its primary endpoint, with an ORR of 67% (14/21). The rates of partial response, very good partial response, and complete response were 29%, 29%, and 10%, respectively (n = 6, 6, and 2). Fourteen patients (67%) achieved renal response. After median follow-up of 28 months, median progression-free survival was 10.4 months; median overall survival was not reached. Higher-grade toxicity was mainly hematologic, and non-hematologic toxicities ≥Grade 3 were mostly infections (24%). The prospective GMMG-DANTE trial investigating DVd exclusively in r/rMM patients with severe RI showed efficacy and safety to be comparable to data from patients without RI.Keywords
Funding Information
- Janssen-Cilag
- University Medical Center Hamburg-Eppendorf
This publication has 24 references indexed in Scilit:
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood, 2016
- International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal ImpairmentJournal of Clinical Oncology, 2016
- International Myeloma Working Group updated criteria for the diagnosis of multiple myelomaThe Lancet Oncology, 2014
- The Use of Novel Drugs Can Effectively Improve Response, Delay Relapse and Enhance Overall Survival in Multiple Myeloma Patients with Renal ImpairmentPLOS ONE, 2014
- Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agentsAnnals of Oncology, 2014
- The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myelomaLeukemia, 2012
- Novel approaches for reducing free light chains in patients with myeloma kidneyNature Reviews Nephrology, 2012
- Incidence and outcome of patients starting renal replacement therapy for end-stage renal disease due to multiple myeloma or light-chain deposit disease: an ERA-EDTA Registry studyNephrology Dialysis Transplantation, 2009
- Expressing the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate with Standardized Serum Creatinine ValuesClinical Chemistry, 2007
- Long-term follow-up of IgM monoclonal gammopathy of undetermined significanceBlood, 2003